MySmile

Feasibility study: To assess whether reducing periodontal infection (gum disease) slows the progression of cognitive impairment associated with Alzheimer's disease (MySmile) 

Summary

Aim: To find out whether treatment which restores gum health in Alzheimer s patients with gum disease (periodontitis), slows down their rate of memory loss. Background: Alzheimer s disease is an inflammatory disease of the brain causing memory loss, confusion and difficulties coping with daily life. It is the major cause of dementia, affecting 500,000 people in the UK with an estimated cost of £23 billion/year to the UK economy, including £3.2 billion to the NHS. It is estimated that any treatment which delays Alzheimer's disease onset by five years would reduce Alzheimer s sufferers by a third and benefit quality of life for patients and carers. Our research group and others have found links between Alzheimer s and gum disease. Gum disease occurs when certain bacteria thrive under the gum line causing inflammation and bleeding. There is good evidence these bacteria pass into the bloodstream and speed up, or cause development of other diseases (such as diabetes and heart disease). Design and methods: We are a highly experienced research team of medical clinicians, dentists and scientists. This study monitors Alzheimer s patients treated for gum disease for 12-months to see if this also slows their rate of memory loss. We have already carried out a small study to see if Alzheimer s patients can cope with the treatment required to manage their gum disease. In most cases it showed gums can become, and stay healthy with a personalised dental plan for at least 1-year. The new study will compare two groups of patients who have both early Alzheimer s and gum disease. One group will continue to look after their teeth and attend their own dental practice as usual. The other group will receive a personalised mouth care plan with all treatment provided at Bristol Dental Hospital or an accredited General Dental Practice. Patient and public involvement (PPI): We have had many discussions with patients, friends, carers and families at public and patient involvement meetings at venues such as Memory cafés. These conversations have not only helped us to design the study but have strengthened our belief in its importance. These meetings will continue throughout the trial to tell everyone about our progress and ask for advice about matters which call for PPI knowledge and awareness. Dissemination: Throughout, we will keep everyone informed by means of talks, publications and social media posts. Slowing the progress of Alzheimer s by improving dental health could dramatically improve quality of life for sufferers and carers. If the study provides evidence to support a larger trial and shows the personalised dental care plan is helping, we would be able to strongly recommend the use of a personalised dental plan for the treatment of Alzheimer s patients within existing frameworks of care.

Further Information

https://www.fundingawards.nihr.ac.uk/award/NIHR203048